0817 GMT - A Bayer breakup looks possible, but it shouldn't be taken for granted even if the U.S. Supreme Court ruled in the company's favor in a case over its Roundup weedkiller, Jefferies analysts say in a research note. While many think the Supreme Court ruling could make a breakup more likely, the challenges the group's pharma business would face as a standalone company remain a potential hurdle, the analysts say. The German group's pharma business is expected to grow at a slower pace than peers over the next five years, and a couple of drugs that should help drive that growth will face risk from rival products, they add. Moreover, its drug pipeline is at an early stage, and its debt load leaves little room for acquisitions, according to Jefferies. Shares fall 0.6%. (adria.calatayud@wsj.com)

(END) Dow Jones Newswires

June 26, 2026 04:20 ET (08:20 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.